( CAMBRIDGE Mass. March 06 2007 /PRNe...)Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings,Health

CAMBRIDGE, Mass., March 06, 2007 /PRNewswire-FirstCall/ -- Advanced Magnetics today announced that data from three completed Phase III multi- center clinical studies of ferumoxytol as an intravenous iron replacement therapeutic will be presented during the National Kidney Foundation (NKF) 2007 Spring Clinical Meetings taking place April 10th through 14th in Orlando, Florida. Two posters containing the data are scheduled to be presented on Wednesday, April 11, 2007 at approximately 5:30 pm ET.

One poster will include data from the company's two completed studies in non dialysis-dependent chronic kidney disease (NDD-CKD) patients. The company plans to present additional data from its first NDD-CKD study, protocol 62,745-6, for which initial data was presented at the American Society of Nephrology Renal Week 2006 Annual Meeting in November 2006. This safety and efficacy study enrolled 304 NDD-CKD patients who were randomized to receive either two 510 mg doses of ferumoxytol within one week or 200 mg of oral iron daily for three weeks. The primary endpoint in the study was the mean change in hemoglobin from baseline in the ferumoxytol group compared to that in the oral iron treatment group. Results from the second NDD-CKD study, protocol 62,745-7, which completed enrollment in November 2006 will also be presented in this poster. This safety and efficacy study also enrolled 304 NDD-CKD patients who were randomized to receive either two 510 mg doses of ferumoxytol within one week or 200 mg of oral iron daily for three weeks. The primary endpoint in the study was also the mean change in hemoglobin from baseline in the ferumoxytol group compared to that in the oral iron treatment group.

The second poster will include data from the company's large scale safety study in both dialysis-dependent (DD-CKD) and NDD-CKD patients, protocol 62,745-8, which completed enrollment in September 2006. This study enrolled
'"/>